M. Weinberger

Adaptive control with feedback strategies for suramin dosing

M. R. Cooper, C. Peck, D. Headlee, 1992, Clinical pharmacology and therapeutics.

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

D. Samid, D. Venzon, W. Figg, 1994, Cancer research.

Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer.

C. Bennett, T. Kuzel, O. Sartor, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

S. Steinberg, W. M. Linehan, O. Sartor, 1994, Journal of the National Cancer Institute.

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response

O. Sartor, W. Figg, D. Headlee, 1996, Cancer Chemotherapy and Pharmacology.

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer.

O. Sartor, W. Figg, A. Li, 1998, Urology.

A Phase I and Pharmacokinetic Study of Intravenous Phenylacetate in Patients with Cancer 1

D. Venzon, W. Figg, D. Headlee, 2006 .

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

W. Figg, D. Headlee, A. Tompkins, 1994, Cancer research.

Urological Survey: Abstracts: Benign and Malignant Neoplasms of ProstateEffect of Prednisone on Prostate-Specific Antigen in Patients With Hormone-Refractory Prostate Cancer

W. Figg, M. Weinberger, A. Moore, 1999 .